Issue | Title | Abstract | File |
No 13S (2018) | 2017 Events (from open information sources) | Abstract |
(Rus) |
Article E. | |||
No 9 (2020) | 3D printing in pharmacy | Abstract |
(Rus) |
Prozherina Y. | |||
No 9 (2020) | A breakthrough in the treatment of chronic lymphocytic leukemia | Abstract |
(Rus) |
Prozherina Y., Shirokova I. | |||
No 1-3 (2020) | A comparative characteristic of business models of leading pharmaceutical manufacturers: aspects of commercial activities | Abstract |
(Rus) |
Yasinskaya L.E., Trofimova E.O. | |||
No 4-6 (2020) | A comparative characteristic of business models of leading pharmaceutical manufacturers: aspects of investment activities | Abstract |
(Rus) |
Yasinskaya L.E. | |||
No 2 (2021) | A current approach to the treatment of ulcerative colitis: updated recommendations of the American Gastroenterological Association | Abstract |
(Rus) |
Vodovozov A. | |||
No 3 (2018) | A new step in the treatment of «king's diseases» | Abstract |
(Rus) |
Shirokova I., Prozherina J. | |||
No 1 (2022) | A rational approach to the issue of responsible self-treatment through the prism of pharmaceutical counseling | Abstract | |
Oleinikova T.A., Baribina E.S. | |||
No 2 (2021) | A review of tender purchases of L01 group – antineoplastic agents | Abstract |
(Rus) |
Kalinina N. | |||
No 3 (2021) | A structural analysis of sales of drugs for the treatment of chronic hepatitis C in the Russian market | Abstract |
(Rus) |
Tsitlionok E.A., Narkevich I.A., Nemyatykh O.D., Siukaeva D.D., Grinyuk A.S., Lisachenko V.O. | |||
No 4 (2019) | A STUDY OF FACTORS INFLUENCING PHARMACEUTICAL COUNSELING IN VIETNAMESE COMMUNITY PHARMACIES | Abstract |
(Rus) |
Dorofeeva V.V., Tran V.D. | |||
No 3 (2022) | A word about “Soviet penicillin” | Abstract |
(Rus) |
Sherstneva E.V. | |||
No 1 (2022) | Activities of municipalities in the field of drug provision of the population in Russia in the second half of the XIX - early XX century | Abstract | |
Sherstneva E.V., Egorysheva I.V. | |||
No 4-6 (2020) | Advances in synthetic biology and regulatory policy of the state | Abstract |
(Rus) |
Mokhov A.A., Chaplenko A.A., Yavorskiy A.N. | |||
No 12 (2018) | Advertising in the pharm market: evaluation of 2018 practice and forecasts for self-regulation | Abstract |
(Rus) |
Borzova M. | |||
No 12 (2019) | Advertising of prescription drugs: when you can’t have everything and even more | Abstract |
(Rus) |
Borzova M. | |||
No 11 (2019) | Ad\"yuvanty - nastoyashchee i budushchee vaktsin | Abstract |
(Rus) |
Shirokova I. | |||
No 11-12 (2020) | Affordable and modern antithrombotic therapy for atrial fibrillation | Abstract |
(Rus) |
Kalinina N. | |||
No 11-12 (2020) | Agile stockpiles an insurance for drug supply | Abstract |
(Rus) |
Gilissen E., Mulligan C., Tottman S., Troein P. | |||
No 11 (2018) | Aleksandr Ametov: instrumentom importozameshcheniya dolzhen stat' gosudarstvennyy registr sakharnogo diabeta | Abstract |
(Rus) |
Article E. | |||
No 7-8 (2020) | Aleksandr TIKhOMIROV: «Nuzhno nachinat' lechenie kak mozhno ran'she, chtoby potom ne «dogonyat'» tyazheluyu voskhodyashchuyu infektsiyu» | Abstract |
(Rus) |
Article E. | |||
No 10 (2020) | Ambulatornye patsienty s koronavirusom poluchat favipiravir besplatno | Abstract |
(Rus) |
Article E. | |||
No 3 (2022) | Analysis of blood glucose and cholesterol indicators in university students in Kazan for 2018-2020 based on the results of preventive medical examinations | Abstract |
(Rus) |
Mazitov M.R., Shulaev A.V., Ziatdinov A.I., Ganeev K.A. | |||
No 5 (2019) | Analysis of compliance with the rules of vacation prescription medicines from pharmacies | Abstract |
(Rus) |
Moroz T.L., Ryzhova O.A. | |||
No 7-8 (2020) | Analysis of current issues for development of pharmaceutical products export in the russian federation: the case of biotechnology enterprise | Abstract |
(Rus) |
Trukhin V.P., Narkevich I.A., Nacharova E.P., Basakina I.I., Poliakova I.N. | |||
No 5 (2018) | Analysis of development trends of the pharmaceutical market of non-steroidal anti-inflammatory drugs in Russia | Abstract |
(Rus) |
Oleynikova T.A., Pozhidaeva D.N. | |||
No 7-8 (2020) | Analysis of foreign experience in training personnelfor the pharmaceutical industry in the European Union | Abstract |
(Rus) |
Budenkova E.A., Litvinova T.M. | |||
No 4 (2019) | ANALYSIS OF PATENT PORTFOLIOS IN THE ANTI-INFLUENZA DRUG SEGMENT | Abstract |
(Rus) |
Vyukhin M., Rodnin A., Shulgin V. | |||
No 12 (2018) | Analysis of patent portfolios of anticancer drugs | Abstract |
(Rus) |
Viukhin M., Shulgin V., Bushueva M. | |||
No 11-12 (2020) | Analysis of performance indicators of the High-cost Nosologies program in the constituent entities of the Russian Federation | Abstract |
(Rus) |
Petrukhina I.K., Yagudina R.I., Ryazanova T.K., Gladunova E.P., Egorova A.V., Khusainova A.I., Blinkova P.R., Loginova L.V. | |||
No 3 (2022) | Analysis of the budget expenditure for rare diseases in the subjects of the Russian Federation | Abstract |
(Rus) |
Komarov I.A., Krasilnikova E.Y., Aleksandrova O.Y. | |||
No 4 (2022) | Analysis of the completeness of the russian market of over-the-counter medicines for the treatment of neurotic disorders | Abstract |
(Rus) |
Oleynikova T.A., Barybina E.S. | |||
No 7-8 (2019) | Analysis of the drug assortment for palliative care for children in the Russian Federation | Abstract |
(Rus) |
Narkevich I.A., Nemyatykh O.D., Medvedeva D.M., Vrubel E.T. | |||
No 13S (2018) | Analysis of the FFP Tender Market in 2017 | Abstract |
(Rus) |
Article E. | |||
No 7-8 (2020) | Analysis of the market of products based on plant-based raw materials used in urology | Abstract |
(Rus) |
Safonova N.V., Trofimova E.O. | |||
No 10 (2019) | Analysis of the Russian paediatric antibacterials market | Abstract |
(Rus) |
Narkevich I.A., Nemyatykh O.D., Medvedeva D.M., Ladut'ko Y.M., Terninko T.M., Zagalov D.E., Mikhaylova Y.V. | |||
No 3 (2021) | Andrey DANILOV: «Khronicheskaya bol' – eto uzhe ne epidemiya, a pandemiya» | Abstract |
(Rus) |
- -. | |||
No 1-3 (2020) | Andrey Danilov: «Ser'eznoy problemoy ostaetsya pravil'noe ponimanie prirody khronicheskoy boli» | Abstract |
(Rus) |
Article E. | |||
No 11-12 (2020) | Anticoagulant group tender review | Abstract |
(Rus) |
Kalinina N. | |||
No 4-6 (2020) | Antipsychotic drugs market: issues of regional procurement | Abstract |
(Rus) |
Prozherina Y. | |||
No 10 (2020) | AnviMax®: optimal drug to combat ARVI and influenza | Abstract |
(Rus) |
Kalinina N. | |||
No 1 (2022) | Application of the ATC/DDD methodology in predicting the need for genetically engineered biological products used to treat patients with rheumatic diseases in a hospital setting | Abstract | |
Ugoltsova V.N., Shakirova D.K., Abdulganieva D.I., Safiullin R.S. | |||
No 11 (2018) | Armais Kamalov: «Segodnya ochen' vazhno sfokusirovat' vnimanie na aktivnom dolgoletii muzhchin» | Abstract |
(Rus) |
Article E. | |||
No 4 (2018) | Artificial intelligence in health care: the system problems | Abstract |
(Rus) |
Kolesnichenko O.Y., Kolesnichenko Y.Y., Litvak D... | |||
No 1-3 (2020) | Assessing the relationship between deviations from GMP requirements and potential quality defects of medicinal products:a survey of employees of the pharmaceutical inspectorate | Abstract |
(Rus) |
Orlov V.A., Shestakov V.N. | |||
No 1 (2022) | Assessment of problems in the organization of day hospitals | Abstract | |
Fayzullina R.N., Gilmanov A.A., Iskandarov I.R. | |||
No 1 (2022) | Assortment analysis of the pharmaceutical online market of over-the-counter drugs for external use in thermal burns | Abstract | |
Lukoyanova I.E., Egorova S.N. | |||
No 2 (2021) | Atrial fibrillation: key aspects of therapy and place of DOAC | Abstract |
(Rus) |
Prozherina Y. | |||
No 11 (2019) | Bayer v dialoge s rossiyskimi spetsialistami zdravookhraneniya | Abstract |
(Rus) |
Article E. | |||
No 7-8 (2020) | Beyond the Future | Abstract |
(Rus) |
Prozherina Y. | |||
No 12 (2019) | Big Data Analytics of EHRs: pathogenic relations of cancer with Ischaemic Heart Disease and Diabetes Mellitus | Abstract |
(Rus) |
Kolesnichenko O.Y., Kolesnichenko Y.Y., Pulit V.V., Martynov A.V., Sotnik A.Y., Khaykina I.A., Marochkina E.B., Minushkina L.O., Pimenova K.V., Bugakova A.S., Vasilyeva E.Y., Komarov R.N., Golovanov A.V. | |||
No 4 (2021) | Biocompatible drugs-protectors against radiation exposure: a modern view on the problem | Abstract | |
Khabriev R.U., Mingazova E.N., Sidorov V.V., Gureev S.A., Yusupova M.M. | |||
No 3 (2021) | Biosimilars: evolution of approaches to the development, regulation, life cycle control and interchangeability management | Abstract |
(Rus) |
Niyazov R.R., Dranitsyna M.A., Vasiliev A.N., Gavrishina E.V. | |||
No 2 (2021) | Biosimilars: reproduction of the clinical profile using modern biotechnology | Abstract |
(Rus) |
Niyazov R.R., Dranitsyna M.A., Vasiliev A.N., Gavrishina E.V. | |||
No 1-2 (2019) | Blood glucose meters and test strips: pharmacy market | Abstract |
(Rus) |
Prozherina J. | |||
No 6 (2018) | Brief review of judicial practice in the sphere of manufacturing and handling medical products for the period from february to May 2018 | Abstract |
(Rus) |
Borzova M. | |||
No 1 (2022) | Bringing registration dossiers in line with the requirements of the EAEU is the number one priority for pharmaceutical industry enterprises | Abstract | |
Plotnikov A.V., Koroleva T.A. | |||
No 9 (2020) | Bronchial asthma: fundamental changes in the new GINA guidelines(2019) | Abstract |
(Rus) |
Vodovozov A. | |||
No 13S (2018) | Budget segment (exclusive of subsidized drug coverage) | Abstract |
(Rus) |
Article E. | |||
No 12 (2019) | Budget segment of the PD market in Russia: results for 9 months of 2019 | Abstract |
(Rus) |
Prozherina Y. | |||
No 4 (2021) | Building a logical-semantic model of the choice of fixed combinations of drugs for treatment of hypertension | Abstract | |
Ibragimova G.Y., Fedotova A.A., Iksanova G.R., Khasanova R.Y., Vasilchenko K.A. | |||
No 4 (2018) | Business activity of medical industry enterprises: net profit rating 2016 | Abstract |
(Rus) |
Romanova S. | |||
No 4 (2018) | Business efficiency of enterprises in the pharmaceutical industry: net profit rating for 2016 | Abstract |
(Rus) |
Romanova S. | |||
No 4 (2018) | Business efficiency of enterprises in the pharmaceutical industry: net profit rating for 2016 | Abstract |
(Rus) |
Romanova S. | |||
No 5 (2018) | Business efficiency of enterprises in the pharmaceutical sector: 2016 net profit rating | Abstract |
(Rus) |
Romanova S. | |||
No 3 (2018) | Business efficiency of enterprises in the pharmaceutical sector: 2016 return on investment rating | Abstract |
(Rus) |
Romanova S. | |||
No 1-2 (2018) | Business efficiency of enterprises in the pharmaceutical sector: sales profit rating for 2016 | Abstract |
(Rus) |
Romanova S. | |||
No 6 (2018) | Business efficiency of enterprises in the pharmaceutical sector: stock turnover rating for 2016 | Abstract |
(Rus) |
Romanova S. | |||
No 1-2 (2018) | Business performance of pharma industry enterprises: 2016 equity turnover rating | Abstract |
(Rus) |
Romanova S. | |||
No 13S (2018) | Cerebrolysin® is currently enjoying a new lease on life | Abstract |
(Rus) |
Prozherina J. | |||
No 4 (2019) | CHALLENGES AND ISSUES IN OPERATING PERSONNEL MANAGEMENT DURING THE IMPLEMENTATION OF PHARMACEUTICAL QUALITY SYSTEM | Abstract |
(Rus) |
SMIRNOV V.A., GORYACHKIN V.V., SHESTAKOV V.N., ABRAMOVICH R.A. | |||
No 3 (2022) | Changes in body mass index among students from different countries before and during the COVID-19 pandemic | Abstract |
(Rus) |
Mingazov R.N., Gureev S.A., Tliashinov A.O., Mingazova E.N. | |||
No 1-2 (2019) | Changes in VED list: an opportunity that came true | Abstract |
(Rus) |
Prozherina J., Shirokova I. | |||
No 7-8 (2020) | Changing breast cancer prognosis | Abstract |
(Rus) |
Prozherina Y., Shirokova I. | |||
No 11 (2018) | Characterization of export prospect of domestic anti-influenza vaccines in Latin American countries and Carribeans | Abstract |
(Rus) |
Trukhin V.P., Narkevich I.A., Nacharova E.P., Uiba S.V., Basakina I.I. | |||
No 3 (2019) | Chelovek legche perenosit golod, chem poteryu sna. Interv'yu s Ol'goy Vorob'evoy | Abstract |
(Rus) |
Article E. | |||
No 1-3 (2020) | Chem opasna bessonnitsa i kak s ney borot'sya? | Abstract |
(Rus) |
Article E. | |||
No 11 (2019) | Chronic vein diseases: a pressing issue of our time | Abstract |
(Rus) |
Beregovykh R., Prozherina Y. | |||
No 1-2 (2019) | Classification issues of GMP-inspection deficiencies: regulatory practices | Abstract |
(Rus) |
Orlov V.A., Shestakov V.N. | |||
No 9 (2018) | Classification of the Republic of Sakha (Yakutia) municipal districts by level of pharmaceutical aid provided using mathematical methods | Abstract |
(Rus) |
Tarabukina S.M., Moshkova L.V. | |||
No 11 (2018) | Climacteric syndrome: issues in modern pharmacotherapy | Abstract |
(Rus) |
Prozherina J., Ilyukhina E. | |||
No 1-2 (2019) | clinical guidelines. history of creation and development in the Russian Federation and abroad | Abstract |
(Rus) |
Kovaleva M.Y., Sukhorukikh O.A. | |||
No 11-12 (2020) | Clinical trials in the Coronavirus era: management of risks | Abstract |
(Rus) |
Vodovozov A. | |||
No 1-2 (2018) | Collecting of organizations' tax debts from its executives: how and when? | Abstract |
(Rus) |
Lavrentieva A. | |||
No 9 (2019) | Combination of private and public interests in the legal regulation of gene technologies | Abstract |
(Rus) |
Mokhov А.А., Yavorskiy A.N. | |||
No 10 (2020) | Comorbid patient with non-alcoholic fatty liver disease | Abstract |
(Rus) |
Shirokova E.N. | |||
No 10 (2020) | Comparative analysis of business models of top pharmaceutical manufacturing companies: financial analysis | Abstract |
(Rus) |
Yasinskaya L.E. | |||
No 9 (2020) | Comparison and analysis of the fda approved orphane drugs register and the vital and essential drugs list of the Russian Federation | Abstract |
(Rus) |
Yurochkin D.S., Leshkevich A.A., Golant Z.M., Narkevich I.A. | |||
No 7-8 (2018) | Conceptual issues of the federal state supervision reform in the sphere of circulation of drugs | Abstract |
(Rus) |
Shevyrev D.N. | |||
No 4 (2021) | Conflict of interest in retail sales of medicines: raising an issue | Abstract | |
Matveev A.G., Mezentseva E.S. | |||
No 11 (2019) | Construct validation and reliability analysis of a questionnaire to evaluate the factors influencing pharmacy staff's recommendation of over-the-counter drugs in Vietnam | Abstract |
(Rus) |
Tran V.D., Dorofeeva V.V., Lagutkina T.P. | |||
No 12 (2019) | Contract manufacturing and R&D: emerging trends for the global pharmaceutical market | Abstract |
(Rus) |
Prozherina Y. | |||
No 3 (2018) | Contribution of the european forum for good clinical practice to improvement of the clinical trial process in Russia and other post-soviet countries | Abstract |
(Rus) |
Kubar O.I. | |||
No 4 (2022) | Corporate social policy of the company as a basis for the development of solutions in the field of health management: review of foreign literature | Abstract |
(Rus) |
Zudin A.B., Vvedensky A.I., Krekova M.M. | |||
No 11 (2018) | Cough and cold combinations market: what do Russians choose? | Abstract |
(Rus) |
Prozherina J. | |||
No 2 (2022) | COVID-19 burden: emotions of fear in healthcare providers | Abstract |
(Rus) |
Goncharenko E.V., Sagitova G.R., Murzova O.A., Shaforostova E.M. | |||
No 4-6 (2020) | COVID-19 vaccine: seeking salvage | Abstract |
(Rus) |
Prozherina Y. | |||
No 2 (2021) | COVID-19: not by vaccine alone | Abstract |
(Rus) |
Gandel V. | |||
No 1 (2021) | CRA University - School of Clinical Trial Monitors: 10 years of success | Abstract |
(Rus) |
Semenov-Tyan-Shanskiy V.L., Bal’Tserovich A.S., Sazonova A.N., Loginovskaya O.A., Verbitskaya E.V., Malikova E.A., Kolbin A.S., Zvartau E.E., Pavlovich D.M. | |||
No 1-3 (2020) | Curbing the insomnia epidemic | Abstract |
(Rus) |
Prozherina Y. | |||
1 - 100 of 611 Items | 1 2 3 4 5 6 7 > >> |